OVERVIEW
Sinus spacers/stents are devices that are used postoperatively following endoscopic sinus surgery (ESS). The intent of these devices is to maintain patency of the sinus openings in the postoperative period, and/or to serve as a local drug delivery vehicle. Reducing postoperative inflammation and maintaining patency of the sinuses may be important in achieving optimal sinus drainage and may impact recovery from surgery.

PRIOR AUTHORIZATION
Prior Authorization is not required.

POLICY STATEMENT
BlueCHiP for Medicare members:
Implantable sinus spacers and stents for postoperative use following endoscopic sinus surgery is covered but not separately reimbursed.

Commercial Products:
Implantable sinus spacers and stents for postoperative use following endoscopic sinus surgery is considered not medically necessary for as there is insufficient published, peer-reviewed scientific literature that demonstrates that the procedure/service is effective.

MEDICAL CRITERIA
None.

BACKGROUND
Endoscopic sinus surgery (ESS) is typically performed in patients with chronic rhinosinusitis unresponsive to conservative treatment. The surgery is associated with improvements in symptoms in up to 90% of more appropriately selected patients. Because of the high success rates and minimally invasive approach, these procedures have rapidly increased in frequency, with an estimated 250,000 procedures performed annually in the U.S. (1) They can be done either in the physician’s office under local anesthesia or in the hospital setting under general anesthesia.

ESS involves the removal of small pieces of bone, polyps, and debridement of tissue within the sinus cavities. There are a number of variations on the specific approach, depending on the disorders that are being treated and the preferences of the treating surgeon. For all procedures, there is a substantial amount of postoperative inflammation and swelling, and postoperative care is therefore a crucial component of ESS.

There are a number of postoperative treatment regimens, and the optimal regimen is not certain. Options include saline irrigation, nasal packs, topical steroids, systemic steroids, topical decongestants, oral antibiotics, and/or sinus cavity debridement. There have been a number of randomized controlled trials (RCTs) that have evaluated various treatment options, but all different strategies have not been rigorously evaluated. (2-5) A systematic review evaluated the evidence for these therapies. (1) The authors of this review concluded that the evidence was not strong for any of these treatments but that some clinical trial evidence supported improvements in outcomes. The strongest evidence was for use of nasal saline irrigation, topical nasal steroid spray, and sinus cavity debridement.
Some form of sinus packing is generally performed postoperatively. Simple dressings moistened with saline can be inserted manually following surgery. Foam dressings are polysaccharide substances that form a gel when hydrated and can be used as nasal packs for a variety of indications. (1) Middle meatal spacers are splint-like devices that prop open the sinus cavities post-ESS, but are not capable of drug delivery. There is some RCT evidence that middle meatal spacers may reduce the formation of synechiae following ESS, although the available studies have significant heterogeneity in this outcome. (6)

Implantable sinus stents/spacers are another option for postoperative management following ESS. These implants are inserted via catheters under endoscopic guidance. These devices may stabilize the sinus openings and the turbinates, reduce edema, and/or prevent obstruction by adhesions. They also have the capability of being infused with medication that can be delivered topically over an extended period of time, and this local delivery of medications may be superior to topical application in the postoperative setting.

The PROPEL™ system was granted U.S. Food and Drug Administration (FDA) approval under the premarketing approval (PMA) program in August 2011. This device is a self-expanding, bioabsorbable, steroid-eluting stent that is intended for use in the ethmoid sinus. Steroids (mometasone furoate) are embedded in a polyethylene glycol polymer, which allows sustained release of the drug over an approximate duration of 30 days. The device is dissolvable over a period of several weeks, and thereby does not require removal.

The Relieva Stratus™ MicroFlow spacer is a balloon-based device that acts as a spacer and medication delivery system. It was FDA approved under the 510(k) program in October 2011. It is indicated for use as a postoperative spacer to maintain an opening to the sinuses within the first 14 days postoperatively. This device is temporary and requires manual removal after 30 days, with implantation of a new device if needed. It is approved for infusion with saline, but not for use with other medications such as steroids.

Implantable sinus stents/spacers have been used post-ESS with the intent of maintaining patency of the sinuses and delivering local steroids. Two RCTs have compared the Propel™ device with steroids to the same device without steroids and reported that the steroid-eluting device reduced postoperative inflammation, reduced the need for oral steroids, and reduced the need for postoperative re-interventions. These trials primarily evaluate the efficacy of topical steroids when delivered by an implanted device, but do not evaluate the efficacy of the device itself versus standard care. The improvements reported in these trials reflect the impact of local steroids, which were withheld in the control arm, as well as the impact of the spacer device itself.

This evidence is insufficient to determine whether sinus spacers and stents improve outcomes when used postoperatively following ESS. Further RCTs are needed that compare the devices to optimal postoperative care without the device to determine whether they can improve postoperative outcomes for patients undergoing ESS, therefore implantable sinus spacers are considered not medically necessary as there is no proven efficacy.

Endoscopic sinus surgery is typically performed in patients with chronic rhinosinusitis unresponsive to conservative treatment. Improvements are associated in symptoms in up to 90% of more appropriately selected patients. Because of the high success rates and minimally invasive approach, these procedures have rapidly increased in frequency, with an estimated 250,000 procedures performed yearly in the US. (1) They can be done either in the doctor’s office under local anesthesia or in the hospital setting under general anesthesia.

Endoscopic sinus surgery involves the removal of small pieces of bone, polyps, and debridement of tissue within the sinus cavities. There are a number of variations on the specific approach, depending on the disorders that are being treated, and preferences of the treating surgeon. For all procedures, there is a
substantial amount of postoperative inflammation and swelling, and postoperative care is therefore a crucial component of the surgery.

While there are a number of postoperative treatment regimens, the optimal regimen is not certain. Options include saline irrigation, nasal packs, topical steroids, systemic steroids, topical decongestants, oral antibiotics, and/or sinus cavity debridement. There have been a number of randomized controlled trials that have evaluated various treatment options, but not all different strategies have been rigorously evaluated. A systematic review evaluated the evidence for these therapies. The authors of this review concluded that the evidence was not strong for any of these treatments, but that some clinical trial evidence supported improvements in outcomes. The strongest evidence supported the use of nasal saline irrigation, topical nasal steroid spray, and sinus cavity debridement.

Some form of sinus packing is generally performed postoperatively. Simple dressings moistened with saline may be inserted manually following surgery. Foam dressings are polysaccharide substances that form a gel when hydrated and can be used as nasal packs for a variety of indications. Middle meatal spacers are splint-like devices that prop open the sinus cavities post surgery, but are not capable of drug delivery. There is some evidence that middle meatal spacers may reduce the formation of synechiae following surgery.

Sinus spacers/stents are devices used postoperatively following endoscopic sinus surgery. The intent of these devices is to maintain patency of the sinus openings in the postoperative period, and/or deliver local medication. Reducing postoperative inflammation and maintaining patency of the sinuses may be important in achieving optimal sinus drainage and may impact recovery from surgery. These are distinguished from sinus packing and variations on packing devices that are routinely employed post sinus surgery. The PROPEL™ system was granted FDA approval under the PMA program in August 2011. This device is a self-expanding, bioabsorbable, steroid eluting stent that is intended for use in the ethmoid sinus. Steroids (mometasone furoate) are embedded in a polyethylene glycol polymer, which allows sustained release of the drug over an approximate duration of 30 days. The device is dissolvable over a period of several weeks, and thereby does not require removal.

The Relieva Stratus™ MicroFlow spacer is a balloon-based device that acts as a spacer and medication delivery system. It was FDA approved under the 510(k) program in October 2011. It is indicated for use as a postoperative spacer to maintain an opening to the sinuses within the first 14 days postoperatively. This device is temporary and requires manual removal after 30 days, with implantation of a new device if needed. It is approved for infusion with saline, but not for use with other medications such as steroids.

Currently there is insufficient evidence to determine whether sinus spacers and stents improve outcomes when used postoperatively following ESS. Further RCTs are needed that compare the devices to optimal postoperative care without the device to determine whether they can improve postoperative outcomes for patients undergoing ESS. Therefore implantable sinus spacers and stents for postoperative use following endoscopic sinus surgery is considered not medically necessary.

**COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate member certificate/subscriber agreement for applicable surgery/not medically necessary coverage/benefits

**CODING**

There are no specific CPT codes for insertion of these devices.

The following HCPCS code for Propel device is not separately reimbursed for BlueChiP for Medicare members and not medically necessary for all other members.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1090</td>
<td>Mometasone furoate sinus implant, 370 micrograms.</td>
</tr>
</tbody>
</table>
RELATED POLICIES
None

PUBLISHED
Provider Update 2013
Provider Update Jan 2013

REFERENCES


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.